CYTK Share Price

Open 14.00 Change Price %
High 14.50 1 Day 0.65 4.69
Low 13.85 1 Week 0.65 4.69
Close 14.50 1 Month 0.05 0.35
Volume 347661 1 Year 4.65 47.21
52 Week High 17.20
52 Week Low 8.51
CYTK Important Levels
Resistance 2 15.10
Resistance 1 14.85
Pivot 14.28
Support 1 14.15
Support 2 13.90
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
ASTI 0.00 0.00%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
More..
NASDAQ USA Top Gainers Stocks
TEAR 3.34 89.77%
SCHS 0.05 66.67%
LOCM 0.09 50.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
TOPS 0.26 23.81%
BONT 0.80 17.65%
HAUP 0.07 16.67%
PLUG 2.44 15.09%
More..
NASDAQ USA Top Losers Stocks
DEER 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Cytokinetics, Incorporated (NASDAQ: CYTK)

CYTK Technical Analysis 3
As on 21st Jul 2017 CYTK Share Price closed @ 14.50 and we RECOMMEND Buy for LONG-TERM with Stoploss of 11.88 & Buy for SHORT-TERM with Stoploss of 13.90 we also expect STOCK to react on Following IMPORTANT LEVELS.
CYTK Target for July
1st Target up-side 13.54
2nd Target up-side 14.56
3rd Target up-side 15.57
1st Target down-side 10.66
2nd Target down-side 9.64
3rd Target down-side 8.63
CYTK Other Details
Segment EQ
Market Capital 85332992.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.cytokinetics.com
CYTK Address
CYTK
280 East Grand Avenue
South San Francisco, CA 94080
United States
Phone: 650-624-3000
Fax: 650-624-3010
CYTK Latest News
Interactive Technical Analysis Chart Cytokinetics, Incorporated ( CYTK NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Cytokinetics, Incorporated
CYTK Business Profile
Cytokinetics, Incorporated (Cytokinetics) is a biopharmaceutical company focused on the discovery and development of small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. The Company�s research and development programs relating to the biology of muscle function are directed to small molecule modulators of the contractility of cardiac, skeletal and smooth muscle. The cardiac muscle contractility program is focused on cardiac sarcomere, the basic unit of muscle contraction in the heart. Its lead drug candidate CK-2017357 is subject of a Phase IIa clinical trials program. CK-2017357 is useful in treating diseases or medical conditions associated with skeletal muscle weakness or wasting. In March 2010, CK-2017357 received an orphan drug designation from the FDA for the treatment of amyotrophic lateral sclerosis.